ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects

American Heart Journal

Volumn 141, Issue 5, 2001, Pages 800-807

  Murdoch, David R ^a   McDonagh, Theresa A ^a   Farmer, Rosemary ^b   Morton, James J ^b   McMurray, John J V ^a   Dargie, Henry J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; NITRATE; PLACEBO; QUINAPRIL; TRANDOLAPRIL; WARFARIN; ACRYLIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; IMIDAZOLE DERIVATIVE; NORADRENALIN; RENIN; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; FATIGUE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMIC PARAMETERS; HUMAN; KIDNEY FUNCTION; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BLOOD; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HEMODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RADIOISOTOPE VENTRICULOGRAPHY; SAFETY; SCINTISCANNING; SWAN GANZ CATHETER;

ACRYLATES; AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CATHETERIZATION, SWAN-GANZ; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NOREPINEPHRINE; PROGNOSIS; PROSPECTIVE STUDIES; RADIONUCLIDE VENTRICULOGRAPHY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN; SAFETY; THIOPHENES;

EID: 0034744446     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.114802     Document Type: Article

References (33)

1. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
2. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: The Randomized Aldactone Evaluation Study (RALES)
3. Aldosterone escape during ACE-inhibitor therapy in chronic heart failure
4. Effect of long-term enalapril therapy on neurohormones in patients with left-ventricular dysfunction
5. Dual pathway for angiotensin II formation in human internal mammary arteries
6. Differences in tissue angiotensin II-forming pathways by species and organs in vitro
7. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
8. Angiotensin II receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
9. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
10. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure: Vasodilator Heart Failure Trial (ValHeFT) Study Group
11. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD pilot study investigators
12. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double-blind, multicentre study
13. Eprosartan does not affect the pharmacodynamics of warfarin
14. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers
15. Effect of age and gender on the pharmacokinetics of eprosartan
16. Pharmacokinetics and protein finding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment
17. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
18. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice
19. An immunoradiometric assay for brain natriuretic peptide in human plasma
20. Radio-immunoassay for plasma alpha human atrial natriuretic peptide: A comparison of direct and pre-extracted methods
21. A microassay for active and total renin concentration in human plasma based on antibody trapping
22. Measurement of plasma angiotensin II
23. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
24. Losartan in heart failure: Hemodynamic effects and tolerability: Losartan Hemodynamic Study Group
25. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison on the hemodynamic and neuroendocrine effects of tailored versus empirical therapy
26. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
27. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction
28. ARCTIC: Assessment of haemodynamic response in patients with congestive heart failure to telmisartan: A multicentre dose-ranging study in Canada
29. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
30. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
31. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design
32. Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure